# Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy

> **NCT05009719** · PHASE1,PHASE2 · COMPLETED · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 50 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **BIOLOGICAL:** Prophylactic Donor lymphocytes infusions
- **BIOLOGICAL:** Preventive Donor lymphocytes infusions

## Key facts

- **NCT ID:** NCT05009719
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2023-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05009719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05009719, "Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05009719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*